Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 and Enzalutamide in CRPC with Bone Metastasis
NCT03305224Phase 2Unknown
- Start
- Oct 2017
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in prostate cancer (PCa), bone metastasis. Status: unknown.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)bone metastasis
Beyond the preview
Go deeper on NCT03305224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305224.